|
1. Biologie
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.13 WCLC
|
|
|
|
|
Pfizer’s son of Xalkori impresses in phase 2 NSCLC trial [Xconomy]
|
|
|
|
|
|
While
part of Pfizer’s plan is to show lorlatinib is better than the
competition at inhibiting the ALK mutations that drive tumor resistance
to Xalkori, the drug’s first-line performance is also a factor. The ORR
and intracranial ORR in these populations came in at 90% and 75%,
respectively.
|
|
|
|
|
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
Copanlisib Approved for Follicular Lymphoma [NCI]
|
|
|
|
|
|
In
the case of copanlisib, the accelerated approval was based on results
from a nonrandomized clinical trial—funded by the drug’s manufacturer,
Bayer—that tested the drug in patients with different types of NHL.
Among the patients in the trial who had follicular lymphoma,
approximately 60% had at least partial reductions in their disease
(partial response).
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.9 Controverses
|
|
|
|
Incyte and Flexus: The Grappling Continues [In the Pipeline]
|
|
|
|
|
|
The
lawsuit says that Flexus changed its whole approach after Fridman
joined and put everything into their IDO program. Incyte’s lawyers
believe that he told them about (confidential) results from their own
program, including useful information about human half-life and trial
design, and they say that they have emails from both Fridman and Flexus
personnel that will show just that.
|
|
|
|
|
|